The Department of Veterans Affairs is launching a nationwide clinical trial to determine whether semaglutide can help treat alcohol use disorder, a condition officially diagnosed in more than 400,000 veterans nationwide, according to department data. VA researchers are studying the GLP-1 receptor agonist—marketed as Ozempic for Type 2 diabetes and Wegovy for chronic weight management—to see if it affects brain regions tied to reward pathways. While the Food and Drug Administration has approved the medication for diabetes and weight control, it is not currently approved for alcohol use disorder.
Understanding the CRAVE Trial Structure
The study is officially known as the Cessation or Reduction of Alcohol Consumption in Veterans (CRAVE) trial. According to department announcements, the project will enroll more than 600 participants between the ages of 18 and 80 across 18 VA medical centers nationwide. Veterans who have moderate or severe alcohol use disorder will receive weekly injections of either semaglutide or a placebo for a 24-week period. Following the treatment phase, researchers will conduct a comprehensive safety evaluation while measuring changes in overall health, quality of life, and alcohol consumption.
Did You Know?
Recruitment for the CRAVE trial officially began on July 28. Veterans interested in participating can contact their local VA medical center or search for the trial directly on ClinicalTrials.gov, according to department guidelines.
Prior Research and Scientific Background
Before launching the current trial, researchers at Washington University School of Medicine studied whether GLP-1 medications could effectively treat substance use disorders. The VA highlighted a published analysis from March showing that patients taking GLP-1 medications experienced lower rates of alcohol use disorder and other substance use issues compared to similar patients taking alternative diabetes medications. Despite these promising observations, department officials emphasized that larger, controlled clinical trials remain necessary to confirm whether semaglutide is both safe and effective specifically for alcohol use disorder.
“By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery,” VA Secretary Doug Collins said in an official statement.
Important Safety Advisory:
The VA strongly cautioned veterans not to self-medicate or replace established, evidence-based alcohol use disorder treatments with GLP-1 medications without first consulting a qualified health care provider.
Frequently Asked Questions
What is the main goal of the CRAVE trial?
The trial aims to determine if semaglutide is safe and effective in helping veterans reduce or cease alcohol consumption by targeting brain receptors involved in reward.
Who is eligible to participate in the study?
Veterans aged 18 to 80 with moderate or severe alcohol use disorder who receive care at participating VA medical centers are eligible for evaluation.
Is semaglutide approved by the FDA for alcohol use disorder?
No. Semaglutide is currently approved only for Type 2 diabetes and chronic weight management, according to federal regulators.
How can veterans sign up for the clinical trial?
Interested individuals can reach out to their local VA medical center or look up the CRAVE trial on ClinicalTrials.gov.
Stay Informed on Veteran Health Policies
Subscribe to our newsletter for ongoing updates regarding military health initiatives, clinical trials, and veterans’ benefits.